| Market Closed - Euronext Paris 16:05:00 2026-11-06 EST | ||
| 8.013 EUR | -0.55% |
|
| Current month | -0.96% | ||
| 1 month | +42.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Receive live all our recommendations
on Turbos and Warrants by Email or WhatsApp.
on Turbos and Warrants by Email or WhatsApp.
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 26-11-06 | €8.013 | -0.55% |
| 26-11-05 | €8.057 | -3.46% |
| 26-11-04 | €8.346 | +7.03% |
| 26-11-03 | €7.798 | -2.01% |
| 26-11-02 | €7.958 | -1.64% |
Static data
| Product type | Knock-Out sin Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| C13ZZ | |
| ISIN | DE000CJ3SH91 |
| Date issued | 2019-02-15 |
| Strike | 7,299.48 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.6100 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.966 € |
|---|---|
| Lowest since issue | 0.2900 € |
| Spread | 0.0790 € |
| Spread % | 0.98% |
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (0.2).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Sector
-
Sell
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
186.17USD
Average target price
215.00USD
Spread / Average Target
+15.49%
- Stock Market
- Certificates
- C13ZZ Certificat
Select your edition
All financial news and data tailored to specific country editions
